MeSH D003586 - cytomegalovirus infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Cidofovir | Cidofovir |  | 2012-06-27 |  |  |
| Valganciclovir | Valganciclovir |  | 2021-03-03 |  |  | |
| Roche | Ganciclovir | Cytovene |  | 1994-12-22 |  |  |
| Cipla | Valganciclovir | Valganciclovir |  | 2018-11-09 |  |  |
| Bausch Health Companies | Ganciclovir | Vitrasert |  | 1996-03-04 |  |  |
| Ganciclovir | Zirgan |  | 2009-09-15 |  |  | |
| Merck & Co | Letermovir | Prevymis |  | 2018-01-08 | $746 M | Q4/23-Q3/24 |
| Takeda | Maribavir | Livtencity |  | 2022-11-09 |  |  |
| Aurobindo Pharma | Valganciclovir | Valganciclovir |  | 2016-03-31 |  |  |
| Ajanta Pharma | Valganciclovir | Valganciclovir |  | 2019-12-26 |  |  |
| Dr Reddys Laboratories | Valganciclovir | Valganciclovir |  | 2014-11-04 |  |  |
| Hetero | Valganciclovir | Valganciclovir |  | 2016-03-18 |  |  |
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
31%4/13
Phase 2
63%5/8
Phase 3
71%12/17
Approved: 5Overall Success rate: 14%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use